Drugs / BMS-986378
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03936465 | Sep 2019 → Mar 2024 | brain cancer, childhood malignant neoplasm, lymphoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986378 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03936465 ↗ |
| Route | Oral | “Patients will receive BMS-986378 (also known as CC-90010) monotherapy orally for 4 days every 28 days.” NCT03936465 ↗ |